Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004904 · ClinicalTrials.gov registry record · Phase 1
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004904: Completed Phase 1 study, sponsored by Northwestern University.
NCT00004904 is a Phase 1 study that has completed, run by Northwestern University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004904, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of treated donor stem cell transplantation in treating patients who have hematologic cancer.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- BIOLOGICAL filgrastim
- BIOLOGICAL anti-thymocyte globulin
- DRUG cladribine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-10 |
| Est. Completion | 2000-07 |
| Phase | Phase 1 |
What the finished NCT00004904 record still lists
NCT00004904 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00004904 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004904 about?
NCT00004904 is a clinical study titled "Stem Cell Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of treated donor stem cell transplantation in treating patients who have hematolo...
What is the current status of trial NCT00004904?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-10. Estimated completion is 2000-07.
What interventions are being tested in trial NCT00004904?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), filgrastim (BIOLOGICAL), anti-thymocyte globulin (BIOLOGICAL), cladribine (DRUG).
Who is sponsoring clinical trial NCT00004904?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia